Navigation Links
ViroPharma to Present at Three November Healthcare Conferences
Date:11/6/2008

EXTON, Pa., Nov. 6 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the Rodman & Renshaw Annual Global Investment Conference at 12:25 P.M. ET on Wednesday, November 12, 2008. The conference is being held at the New York Palace Hotel.

ViroPharma also announced that Colin Broom, vice president, chief scientific officer of ViroPharma will present at the Lazard Capital Markets 5th Annual Healthcare Conference at 9:30 A.M. ET on Wednesday, November 19, 2008. The conference is being held at the St. Regis Hotel in New York.

William Roberts, vice president, corporate communications of ViroPharma will present at the Needham & Company Focus on Infectious Disease Conference at 9:30 A.M. ET on Thursday, November 20, 2008. The conference is being held at Needham & Company's corporate headquarters in New York.

ViroPharma's presentations will be webcast live for investors through http://www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) (vancomycin hydrochloride capsules, USP), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains, and Cinryze(TM) (C1 inhibitor (human)) for routine
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
2. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
3. ViroPharma to Present at Three October Healthcare Conferences
4. ViroPharma to Present at Three September Healthcare Conferences
5. ViroPharma To Acquire Lev Pharmaceuticals
6. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
7. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
8. ViroPharma to Present at Two Upcoming Healthcare Conferences
9. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
10. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
11. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... BETHESDA, Md. , April 1, 2015 /PRNewswire/ ... development company committed to the fostering and monetization ... Markets LLC, a privately held full service global ... companies, recently issued an industry note featuring Spherix. ... McIlree , CFA, a Senior Analyst at Chardan, ...
(Date:4/1/2015)... CA (PRWEB) April 01, 2015 The concept ... loss, a multi-billion dollar industry. Founder of Fasciology, Ashley Black, ... an area of fat, instead of having to wait for ... Black claims that “ prior to fat cooling procedures, ... sculpting or contouring, was liposuction, which is a highly invasive ...
(Date:4/1/2015)... 2015 National recruitment firm Slone ... Brad Allen as Head of Sales at Optimal Medicine, ... market. , Allen brings over 20 years experience ... a number of companies including Dell Services Healthcare, Medsphere ... were a perfect fit for accomplishing the goals Optimal ...
(Date:3/31/2015)... 31, 2015 CytoSorbents Corporation (NASDAQ CM: ... purification to treat critically-ill and cardiac surgery patients ... and reports financial results for the fiscal year ... CytoSorb® product revenues were a record $3.1M, an ... CytoSorb® revenues of $0.8M Highlights for the Year ...
Breaking Biology Technology:Chardan Capital Issues Industry Note Covering Spherix 2Chardan Capital Issues Industry Note Covering Spherix 3Hybrid Health Guru, Ashley Black, announces that her invention The FasciaBlaster™ rivals the “fat cooling” procedures that reduce exercise and diet resistant fat pockets. 2Hybrid Health Guru, Ashley Black, announces that her invention The FasciaBlaster™ rivals the “fat cooling” procedures that reduce exercise and diet resistant fat pockets. 3Slone Partners Fills Head of Sales at Optimal Medicine 2CytoSorbents Reports Record 2014 Revenue 2CytoSorbents Reports Record 2014 Revenue 3CytoSorbents Reports Record 2014 Revenue 4CytoSorbents Reports Record 2014 Revenue 5CytoSorbents Reports Record 2014 Revenue 6CytoSorbents Reports Record 2014 Revenue 7CytoSorbents Reports Record 2014 Revenue 8CytoSorbents Reports Record 2014 Revenue 9CytoSorbents Reports Record 2014 Revenue 10CytoSorbents Reports Record 2014 Revenue 11
... Pharmaceuticals is,pleased to announce the introduction of ... on medically based aesthetics and,utilize the clinical ... of,science-based, result-oriented products., Vitivia(TM),s first product ... have long been recognized as important tools ...
... 27 Debiopharm Group,(Debiopharm), a global independent ... and particularly oncology, today,announced the establishment of ... Federale de Lausanne (EPFL), focusing on Signal ... million endowment, the objective,of the chair is ...
... combination vaccine against Ebola and Marburg viruses using ... infection in monkeys. Researchers from the U.S. ... report their results today (Feb. 26) at the ... in Baltimore, MD. , VLPs are one of ...
Cached Biology Technology:JSJ Pharmaceuticals Announces Launch of Aesthetic Division - Vitivia(TM) 2Debiopharm and EPFL Establish an Oncology Chair 2Combination vaccine protects monkeys from ebola and Marburg viruses 2
(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
(Date:3/24/2015)... --  NexID Biometrics LLC, whose spoof-mitigation technology boosts ... the beginning of shipments of version 2.0 of its ... based in Potsdam, N.Y. , is ... began here today at the Walter E. Washington Convention ... SDK boosts the accuracy rate range to 96.5 to ...
(Date:3/23/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), a ... announces its biometric payment technology, the Wocket® smart wallet, will ... 30 th . The new 30 ... markets. Gino Pereira , ... ad campaign following the recent initial shipment of Wocket smart ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3
... Researchers at Loyola University Chicago Stritch School of ... the National Institutes of Health to study vitamin D ... evaluate the relation between low vitamin D levels and ... disease. Evidence from numerous previous studies is "inconclusive ...
... N.C. Researchers at the University of North Carolina at ... and paste together different viruses in an effort to create ... clinical trial, the investigators found no side effects from using ... muscle protein in patients with muscular dystrophy. "This trial ...
... Bethesda, MDUsing magnetic resonance imaging (MRI) and nanoparticle technology, ... the growth of laboratory-engineered blood vessels after they have ... step toward ensuring that blood vessels, and possibly other ... taking hold and working as expected. Until now, there ...
Cached Biology News:Loyola receives NIH grant to study vitamin D deficiency in African populations 2Clinical trial for muscular dystrophy demonstrates safety of customized gene therapy 2Yale researchers develop a way to monitor engineered blood vessels as they grow in patients 2
Rabbit anti-phospho-EGFr (Tyr992) - Concentrate...
... PS603. Immunogen: Synthetic phosphopeptide ... the phosphorylated Ser603 residue of ... Specific for synapsin I when ... Reactivity: Rat (positive control: ...
CMRL Medium-1066 (1X) liquid...
... 11(R)-HETE is biosynthesized by the ... purpuratus, and the fresh water hydra, ... 11(R)-HETE relates to oocyte maturation and ... species.11(R)-HETE is also produced when aspirin-treated ...
Biology Products: